VYNE Therapeutics Investor Relations Material
Latest events
R&D Day 2023
VYNE Therapeutics
Q1 2025
8 May, 2025
Q4 2024
6 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from VYNE Therapeutics Inc
Access all reports
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing proprietary therapeutics for the treatment of immuno-inflammatory conditions. The company's product pipeline includes VYN201, a locally administered pan-BET inhibitor designed to address diseases involving multiple inflammatory cell signaling pathways with minimal systemic exposure. Additionally, VYNE is working on VYN202, a BD2-selective oral small molecule, and FMX114, a combination gel in clinical trials for atopic dermatitis. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
VYNE
Country
🇺🇸 United States